{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:02:27Z","timestamp":1761919347778,"version":"3.37.3"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,10,8]],"date-time":"2007-10-08T00:00:00Z","timestamp":1191801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold>There have been few reports that compare the effect of histamine H2\u2010receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) using continuous gastric pH monitoring for a long duration.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold>To assess the early effects of both drugs on gastric pH using a wireless pH monitoring system.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold>The test was conducted by a cross\u2010over test: 10 healthy male volunteers were administered famotidine 20\u2003mg twice a day and lansoprazole 30\u2003mg once a day. Monitoring of gastric pH over four consecutive days was performed using a unique method we have developed that is an elaboration of the Bravo system.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold>The time to reach a pH level of 3 or more with famotidine was significantly shorter than that for lansoprazole. The pH3 holding time ratio of famotidine during the first 4\u2003h of administration was significantly higher than that of lansoprazole. The pH3 holding time ratio on each day from day 1 to day 3 was significantly higher following lansoprazole administration compared with famotidine administration.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold>Famotidine was shown to act quickly in elevating gastric pH; however, lansoprazole was superior to famotidine in terms of its ability to elevate gastric pH for a long duration.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03545.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T13:55:24Z","timestamp":1279893324000},"page":"66-71","source":"Crossref","is-referenced-by-count":11,"title":["Four\u2010day continuous gastric pH monitoring following anti\u2010acid secretory drug administration: cross\u2010over test to assess the early effects"],"prefix":"10.1111","volume":"27","author":[{"given":"T.","family":"SUZUKI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"YAMAGUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"ODAKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"KOBAYASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"SEZA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"KOUZU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"YOKOSUKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10,8]]},"reference":[{"issue":"2","key":"e_1_2_6_2_2","first-page":"S27","article-title":"Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine","volume":"20","author":"Masahiro S","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"e_1_2_6_3_2","first-page":"291","article-title":"Effect of H2 receptor antagonist and proton pump inhibitor on 24\u2010hour intragastric pH in fasting patients","volume":"18","author":"Masaki I","year":"1997","journal-title":"Ther Res"},{"issue":"1","key":"e_1_2_6_4_2","first-page":"S7","article-title":"Evaluation of the effect of lansoprazole in suppressing acid secretion using 24\u2010hour intragastric pH monitoring","volume":"20","author":"Hiroshi T","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-005-1569-0"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.103242000.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00939.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0022-3565(25)20193-8","article-title":"Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG\u20101749 in isolated canine parietal cells","volume":"252","author":"Nagaya H","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01300386"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)91015-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03126.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199506002-00004"},{"issue":"2","key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/62.10_Supplement_2.S4","article-title":"Overview of pharmacologic agents for acid suppression incritically ill patients","volume":"10","author":"Welage LS","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.1101982"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0455.2003.00033.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07398.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026608804938"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2005.10.028"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03545.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03545.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T08:41:38Z","timestamp":1740300098000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03545.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,8]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03545.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03545.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"type":"print","value":"0269-2813"},{"type":"electronic","value":"1365-2036"}],"subject":[],"published":{"date-parts":[[2007,10,8]]}}}